These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3859929)

  • 41. Low dose cytosine arabinoside in adult acute non-lymphoid leukemia.
    Rossi Ferrini P; Ciolli S; Leoni F
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():36-7. PubMed ID: 2713558
    [No Abstract]   [Full Text] [Related]  

  • 42. Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response.
    Bickers JN; Gehan EA; Freireich EJ; Coltman CA; Wilson HE; Hewlett JS; Stuckey WJ; Van Slyck EJ
    Arch Intern Med; 1974 Feb; 133(2):251-9. PubMed ID: 4521467
    [No Abstract]   [Full Text] [Related]  

  • 43. Prolonged infusion of arabinosyl cytosine in childhood leukemia.
    Wang JJ; Selawry OS; Vietti TJ; Bodey GP
    Cancer; 1970 Jan; 25(1):1-6. PubMed ID: 5262259
    [No Abstract]   [Full Text] [Related]  

  • 44. Maintenance of remission in adult acute nonlymphoblastic leukemia using intermittent courses of cytosine arabinoside (NSC-63878) and 6-thioguanine (NSC-752).
    Armitage JO; Burns CP
    Cancer Treat Rep; 1976 May; 60(5):585-9. PubMed ID: 991147
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low dose cytosine arabinoside in acute myeloid leukemia: remission is not due to differentiation induction.
    Pinkerton PH; London B; Cowan DH
    Am J Hematol; 1985 Aug; 19(4):415-7. PubMed ID: 3861090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia.
    Sanz MA; Martínez J; Borrego D; Martín-Aragonés G; Lorenzo I; Sanz G; Sayas MJ; Jarque I; Pastor E; Rafecas J
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):18-20. PubMed ID: 3589692
    [No Abstract]   [Full Text] [Related]  

  • 47. Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia.
    Fenaux P; Jouet JP; Bauters F
    J Clin Oncol; 1987 Jul; 5(7):1129-30. PubMed ID: 3474358
    [No Abstract]   [Full Text] [Related]  

  • 48. [Low doses of subcutaneous cytosine arabinoside in the treatment of patients with myelodysplastic syndromes].
    Avilés A; Tripp F; Velásquez A; Rubio ME; González-Llavén J
    Rev Invest Clin; 1988; 40(1):21-4. PubMed ID: 3165541
    [No Abstract]   [Full Text] [Related]  

  • 49. High-dose cytosine arabinoside in the consolidation therapy of acute nonlymphocytic leukemia in remission.
    Takaku F; Urabe A; Mizoguchi H; Hoshino S; Toyama K; Tanaka K; Nomura T; Dan K; Fujioka S; Saito T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):55-7. PubMed ID: 3589698
    [No Abstract]   [Full Text] [Related]  

  • 50. [High-dose cytosine arabinoside].
    Seeber S
    Onkologie; 1985 Feb; 8(1):57-8. PubMed ID: 3885124
    [No Abstract]   [Full Text] [Related]  

  • 51. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans.
    Dybedal I; Lamvik J
    Eur J Haematol; 1989 Apr; 42(4):405-6. PubMed ID: 2721663
    [No Abstract]   [Full Text] [Related]  

  • 53. In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.
    Raza A; Ucar K; Preisler HD; Mayers G
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):9-19. PubMed ID: 3892706
    [No Abstract]   [Full Text] [Related]  

  • 54. [Low-dose cytosine arabinoside therapy in relapsed acute leukemia: correlation of clinical response and in vitro sensitivity tests].
    Ninomiya T; Hirose M; Takaue Y; Watanabe T; Ouchi T; Sato J; Koyama T; Abe T; Suzue T
    Rinsho Ketsueki; 1987 Oct; 28(10):1763-70. PubMed ID: 3452642
    [No Abstract]   [Full Text] [Related]  

  • 55. Cytosine arabinoside (NSC-63878) in acute leukemia in children.
    Howard JP; Cevik N; Murphy ML
    Cancer Chemother Rep; 1966 Jul; 50(5):287-91. PubMed ID: 5936999
    [No Abstract]   [Full Text] [Related]  

  • 56. Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults.
    Whitecar JP; Bodey GP; Freireich EJ; McCredie KB; Hart JS
    Cancer Chemother Rep; 1972 Aug; 56(4):543-50. PubMed ID: 5081596
    [No Abstract]   [Full Text] [Related]  

  • 57. Daunorubicin (NSC-82151), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) combination therapy for advanced adult acute leukemia.
    Burns CP
    Cancer Chemother Rep; 1975; 59(4):757-60. PubMed ID: 1100227
    [No Abstract]   [Full Text] [Related]  

  • 58. Adriamycin-cytosine arabinoside therapy for adult acute myelocytic leukemia.
    Preisler HD; Bjornsson S; Henderson ES
    Cancer Treat Rep; 1977; 61(1):89-92. PubMed ID: 324625
    [No Abstract]   [Full Text] [Related]  

  • 59. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H; Breithaupt H
    Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of acute leukemia in adults with cytosine arabinoside and thioguanine].
    Kotlarek-Haus S; Lawińska B; Kuliszkiewicz-Janus M
    Acta Haematol Pol; 1978; 9(4):237-42. PubMed ID: 735711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.